Mannkind price to free cash flow MNKD

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 91.9×; Jul 2026
2-year median: 59.0×
2-year range: 35.6× to 469×
Peer median: 8.1×

Mannkind's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 91.9×.

On the days it had one over the last 2 years, its median was 59.0×, from 35.6× in Nov 2025 to 469× in Aug 2024.

Price to free cash flow over time

median 59×

The dashed line is the 2-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	91.9×	36.9×	106×
2025	41.0×	35.6×	63.5×
2024	65.1×	62.5×	469×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	44.8×	44.8×	63.8×

Against its peers

Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.

Company	Price to free cash flow
MNKDMannkind	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
ABUSArbutus Biopharma	n/m
COLLCollegium Pharmaceutical	2.3×
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
Peer median	8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Mannkind

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.